Search
Bioventus Inc
BVSAdd to Watchlist
12.910USD
+0.280+2.22%
Close 09-17 16:00（ET）
879.25MMarket Cap
30.16P/E TTM
Bioventus Inc (BVS) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Bioventus Inc in the past month.
Buy
1 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
17.600USD+35.38%
BVS Analyst Recommendation Trends
In the current month, BVS has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BVS average Analyst price target in the last month is 17.600.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
0
0
0
4
4
4
4
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
4
3
3
3
BVS Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Stryker Corp
SYK
11
13
6
0
0
30
Medtronic PLC
MDT
9
10
11
0
0
30
Dexcom Inc
DXCM
13
13
4
0
0
30
Zimmer Biomet Holdings Inc
ZBH
2
6
21
0
0
29
Abbott Laboratories
ABT
11
12
6
0
0
29
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Insulet Corp
PODD
7
8
12
0
0
27
Guardant Health Inc
GH
12
13
2
0
0
27
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
14
3
0
0
22
Financial Forecasting
Based on analysts' estimates, BVS EPS is projected to reach 0.155 in FY2026Q3, following reported EPS of 0.493 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.22
0.10
0.22
0.15
0.26
Actual
0.22
0.05
0.49
--
--
Surprise
+1.58%
-52.55%
+128.12%
--
--
FAQs
What is Bioventus Inc's expected revenue for the next quarter?
Bioventus Inc's expected revenue is 149.41M.
What is Bioventus Inc's price target?
Analysts forecast that Bioventus Inc's price target is USD 17.60, with the highest forecast at USD 19.00 and the lowest forecast at USD 15.00.
How have Bioventus IncBVS's recent earnings per share performed?
The market expectation was USD 0.49, while Bioventus IncBVS's earnings per share (EPS) for the previous quarter was USD 0.05. EPS for the next quarter is expected at USD 0.15.
What is the analyst rating for Bioventus Inc?
Based on the ratings of Bioventus Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.